Sabine C Linn

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/258637/publications.pdf

Version: 2024-02-01

116 papers	4,503 citations	117619 34 h-index	114455 63 g-index
118 all docs	118 docs citations	118 times ranked	5590 citing authors

#	Article	IF	Citations
1	Response to Klar and Adams. Journal of the National Cancer Institute, 2022, 114, 167-168.	6.3	0
2	Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients. British Journal of Cancer, 2022, 126, 1401-1409.	6.4	11
3	Pregnancy-associated breast cancer: the influence of gestational age. Endocrine-Related Cancer, 2022, 29, 129-138.	3.1	4
4	Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy. Journal of Clinical Oncology, 2022, 40, 2361-2374.	1.6	45
5	FER regulates endosomal recycling and is a predictor for adjuvant taxane benefit in breast cancer. Cell Reports, 2022, 39, 110584.	6.4	4
6	Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments. Clinical Cancer Research, 2022, 28, 960-971.	7.0	4
7	Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptorâ€“Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial. Journal of Clinical Oncology, 2022, 40, 2934-2945.	1.6	6
8	Effect of <scp>HIPEC</scp> according to <scp>HRD</scp>/<scp>BRCAwt</scp> genomic profile in stage <scp>III</scp> ovarian cancer: Results from the phase <scp>III OVHIPEC</scp> trial. International Journal of Cancer, 2022, 151, 1394-1404.	5.1	15
9	Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature. Breast Cancer Research and Treatment, 2022, , .	2.5	2
10	Predictive value of ectopic HORMAD1 tumor expression for high-dose platinum-based chemotherapy benefit in patients with high-risk HER2-negative breast cancer.. Journal of Clinical Oncology, 2022, 40, 541-541.	1.6	0
11	Immune landscape of breast tumors with low and intermediate estrogen receptor (ER) expression.. Journal of Clinical Oncology, 2022, 40, 566-566.	1.6	1
12	Fertility preservation for women with breast cancer: a multicentre randomized controlled trial on various ovarian stimulation protocols. Human Reproduction, 2022, 37, 1786-1794.	0.9	13
13	Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial. Annals of Oncology, 2021, 32, 58-65.	1.2	14
14	Comprehensive trends in incidence, treatment, survival and mortality of first primary invasive breast cancer stratified by age, stage and receptor subtype in the Netherlands between 1989 and 2017. International Journal of Cancer, 2021, 148, 2289-2303.	5.1	34
15	Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer. Breast Cancer Research and Treatment, 2021, 185, 817-830.	2.5	2
16	A Phase I doseâ€escalation study of two cycles carboplatinâ€olaparib followed by olaparib monotherapy in patients with advanced cancer. International Journal of Cancer, 2021, 148, 3041-3050.	5.1	5
17	Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer. JNCI Cancer Spectrum, 2021, 5, pkab010.	2.9	21
18	Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients. Journal of the National Cancer Institute, 2021, 113, 1506-1514.	6.3	6

#	Article	IF	Citations
19	Simultaneous analysis of E1 and E2 by LC-MS/MS in healthy volunteers: estimation of reference intervals and comparison with a conventional E2 immunoassay. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1178, 122563.	2.3	12
20	Ovarian Cancerâ€"Specific BRCA-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial. Clinical Cancer Research, 2021, 27, 6559-6569.	7.0	9
21	Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (BOOG 2013-01). Breast Care, 2021, 16, 1-9.	1.4	3
22	IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women. Npj Breast Cancer, 2021, 7, 138.	5.2	1
23	IGFâ€1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ERâ€positive breast cancer. International Journal of Cancer, 2020, 146, 2348-2359.	5.1	18
24	Metabolic Imaging Detects Resistance to PI3KÎ± Inhibition Mediated by Persistent FOXM1 Expression in ER+ Breast Cancer. Cancer Cell, 2020, 38, 516-533.e9.	16.8	38
25	Phase I feasibility study of Magnetic Resonance guided High Intensity Focused Ultrasound-induced hyperthermia, Lyso-Thermosensitive Liposomal Doxorubicin and cyclophosphamide in de novo stage IV breast cancer patients: study protocol of the i-GO study. BMJ Open, 2020, 10, e040162.	1.9	19
26	Adjuvant chemotherapy in small node-negative triple-negative breast cancer. European Journal of Cancer, 2020, 135, 66-74.	2.8	20
27	Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial. Breast Cancer Research and Treatment, 2020, 180, 675-685.	2.5	4
28	Hierarchical clustering of PI3K and MAPK pathway proteins in breast cancer intrinsic subtypes. Apmis, 2020, 128, 298-307.	2.0	7
29	High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes. JAMA Oncology, 2020, 6, 528.	7.1	17
30	Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy. European Journal of Cancer, 2020, 127, 240-250.	2.8	21
31	Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes. Breast Cancer Research, 2019, 21, 90.	5.0	81
32	Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)â€"PathIES. Breast Cancer Research and Treatment, 2019, 175, 149-163.	2.5	4
33	Safety of trastuzumab emtansine (T-DM1)Âin patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1. European Journal of Cancer, 2019, 109, 92-102.	2.8	73
34	MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology. Journal of Molecular Diagnostics, 2019, 21, 808-823.	2.8	15
35	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37â€˜298 women with early breast cancer in 26 randomised trials. Lancet, The, 2019, 393, 1440-1452.	13.7	260
36	Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study. International Journal of Cancer, 2019, 145, 1325-1333.	5.1	8

#	Article	IF	Citations
37	Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapyâ€induced ovarian function failure. International Journal of Cancer, 2019, 145, 274-283.	5.1	7
38	Adjuvant chemotherapy in small node-negative triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2019, 37, 536-536.	1.6	3
39	Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study. European Journal of Cancer, 2018, 90, 92-101.	2.8	13
40	PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer. Clinical Pharmacokinetics, 2018, 57, 427-437.	3.5	87
41	Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 1630-1640.	10.7	237
42	Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences. British Journal of Cancer, 2018, 119, 832-839.	6.4	15
43	Adjuvant dose-dense doxorubicin-cyclophosphamideÂversus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04). European Journal of Cancer, 2018, 102, 40-48.	2.8	9
44	<scp>FOXA</scp>1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome. Molecular Oncology, 2018, 12, 1884-1894.	4.6	19
45	Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot. BMC Cancer, 2018, 18, 761.	2.6	7
46	Specific adverse events are associated with response to exemestane therapy in postmenopausal breast cancer patients: Results from the TEAMIIA study (BOOG2006-04). European Journal of Surgical Oncology, 2017, 43, 619-624.	1.0	1
47	Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study. European Journal of Cancer, 2017, 74, 47-54.	2.8	21
48	Estrogen receptor Î± wields treatment-specific enhancers between morphologically similar endometrial tumors. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E1316-E1325.	7.1	25
49	Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years. European Journal of Cancer, 2017, 78, 37-44.	2.8	38
50	(Very) Early technology assessment and translation of predictive biomarkers in breast cancer. Cancer Treatment Reviews, 2017, 52, 117-127.	7.7	13
51	Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. Drugs, 2017, 77, 1313-1336.	10.9	39
52	Ovarian Function Recovery During Anastrozole in Breast Cancer Patients With Chemotherapy-Induced Ovarian Function Failure. Journal of the National Cancer Institute, 2017, 109, .	6.3	19
53	Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial. Lancet Oncology, The, 2017, 18, 1502-1511.	10.7	119
54	BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial. Breast Cancer Research and Treatment, 2017, 166, 775-785.	2.5	2

#	Article	IF	Citations
55	DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. Npj Breast Cancer, 2017, 3, 31.	5.2	64
56	Long-term prognosis of young breast cancer patients (â‰¤40 years) who did not receive adjuvant systemic treatment: protocol for the PARADIGM initiative cohort study. BMJ Open, 2017, 7, e017842.	1.9	11
57	Stimulation of the ovaries in women with breast cancer undergoing fertility preservation: Alternative versus standard stimulation protocols; the study protocol of the STIM-trial. Contemporary Clinical Trials, 2017, 61, 96-100.	1.8	13
58	The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting. Breast Cancer Research, 2017, 19, 99.	5.0	58
59	Impact of 70-Gene Signature Use on Adjuvant Chemotherapy Decisions in Patients With Estrogen Receptorâ€"Positive Early Breast Cancer: Results of a Prospective Cohort Study. Journal of Clinical Oncology, 2017, 35, 2814-2819.	1.6	31
60	Anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure.. Journal of Clinical Oncology, 2017, 35, 523-523.	1.6	1
61	BRCA-like classification in ovarian cancer: Results from the AGO-TR1-trial.. Journal of Clinical Oncology, 2017, 35, 5546-5546.	1.6	3
62	Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy. Oncotarget, 2017, 8, 113531-113542.	1.8	8
63	The Melanoma MAICare Framework: A Microsimulation Model for the Assessment of Individualized Cancer Care. Cancer Informatics, 2016, 15, CIN.S38122.	1.9	1
64	A randomized phase 2 study exploring the role of bevacizumab and a chemotherapyâ€free approach in HER2â€positive metastatic breast cancer: The HAT study (BOOG 2008â€2003), a Dutch Breast Cancer Research Group trial. Cancer, 2016, 122, 2961-2970.	4.1	7
65	The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer. Breast Cancer Research and Treatment, 2016, 158, 361-371.	2.5	26
66	High XIST and Low 53BP1 Expression Predict Poor Outcome after High-Dose Alkylating Chemotherapy in Patients with a BRCA1-like Breast Cancer. Molecular Cancer Therapeutics, 2016, 15, 190-198.	4.1	46
67	Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERÎ± in Tamoxifen-Associated Endometrial Carcinomas. Cancer Research, 2016, 76, 3773-3784.	0.9	30
68	Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study. Breast, 2016, 29, 153-159.	2.2	31
69	A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial. Trials, 2016, 17, 293.	1.6	14
70	Prognostic Value of MammaPrint^{Â®} in Invasive Lobular Breast Cancer. Biomarker Insights, 2016, 11, BMI.S38435.	2.5	31
71	10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study. Lancet Oncology, The, 2016, 17, 1158-1170.	10.7	301
72	BRCA1â€like profile predicts benefit of tandem high dose epirubicinâ€cyclophospamideâ€thiotepa in high risk breast cancer patients randomized in the WSGâ€AM01 trial. International Journal of Cancer, 2016, 139, 882-889.	5.1	16

#	Article	IF	Citations
73	Equivalence of MammaPrint array types in clinical trials and diagnostics. Breast Cancer Research and Treatment, 2016, 156, 279-287.	2.5	57
74	Using a gene expression signature when controversy exists regarding the indication for adjuvant systemic treatment reduces the proportion of patients receiving adjuvant chemotherapy: a nationwide study. Genetics in Medicine, 2016, 18, 720-726.	2.4	13
75	4â€protein signature predicting tamoxifen treatment outcome in recurrent breast cancer. Molecular Oncology, 2016, 10, 24-39.	4.6	31
76	Neoadjuvant tamoxifen synchronizes ERÎ± binding and gene expression profiles related to outcome and proliferation. Oncotarget, 2016, 7, 33901-33918.	1.8	13
77	Optimal endocrine therapy for breast cancer patients 45-50 years of age at diagnosis.. Journal of Clinical Oncology, 2016, 34, 551-551.	1.6	2
78	The value of completion axillary treatment in sentinel node positive breast cancer patients undergoing a mastectomy: a Dutch randomized controlled multicentre trial (BOOG 2013-07). BMC Cancer, 2015, 15, 610.	2.6	65
79	BRCA1â€like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential. Molecular Oncology, 2015, 9, 1528-1538.	4.6	54
80	Tailored Tamoxifen Treatment for Breast Cancer Patients: A Perspective. Clinical Breast Cancer, 2015, 15, 241-244.	2.4	18
81	Challenges in the Use of DNA Repair Deficiency As a Biomarker in Breast Cancer. Journal of Clinical Oncology, 2015, 33, 1867-1869.	1.6	13
82	Robust BRCA1â€like classification of copy number profiles of samples repeated across different datasets and platforms. Molecular Oncology, 2015, 9, 1274-1286.	4.6	29
83	Breast Cancers with aBRCA1-like DNA Copy Number Profile Recur Less Often Than Expected after High-Dose Alkylating Chemotherapy. Clinical Cancer Research, 2015, 21, 763-770.	7.0	34
84	Protein Kinase A-induced tamoxifen resistance is mediated by anchoring protein AKAP13. BMC Cancer, 2015, 15, 588.	2.6	24
85	St. Gallen endocrine response classes predict recurrence rates over time. Breast, 2015, 24, 705-712.	2.2	5
86	Copy number profiling by array comparative genomic hybridization identifies frequently occurring <scp>BRCA</scp>2â€like male breast cancer. Genes Chromosomes and Cancer, 2015, 54, 734-744.	2.8	10
87	Molecular Profiling Is Rather Likely to Be Cost Effective. Journal of Clinical Oncology, 2015, 33, 1626-1627.	1.6	4
88	Ongoing Remission Nineteen Years after High-dose Chemotherapy for Oligometastatic Breast Cancer; What Can We Learn from this Patient?. Cureus, 2015, 7, e433.	0.5	3
89	Lack of Genomic Heterogeneity at High-Resolution aCGH between Primary Breast Cancers and Their Paired Lymph Node Metastases. PLoS ONE, 2014, 9, e103177.	2.5	9
90	PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy. International Journal of Cancer, 2014, 135, 1257-1263.	5.1	23

#	Article	IF	Citations
91	Risk estimations and treatment decisions in early stage breast cancer: Agreement among oncologists and the impact of the 70-gene signature. European Journal of Cancer, 2014, 50, 1045-1054.	2.8	13
92	Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment. Breast Cancer Research, 2014, 16, R6.	5.0	46
93	Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care. Breast Cancer Research and Treatment, 2014, 143, 477-483.	2.5	40
94	Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients â€“ A phase II trial. European Journal of Cancer, 2014, 50, 2190-2200.	2.8	67
95	Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms. Breast Cancer Research and Treatment, 2014, 145, 697-705.	2.5	22
96	PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients. Breast Cancer Research, 2014, 16, R13.	5.0	54
97	Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. Breast Cancer Research, 2014, 16, R47.	5.0	86
98	MammaPrint Molecular Diagnostics on Formalin-Fixed, Paraffin-Embedded Tissue. Journal of Molecular Diagnostics, 2014, 16, 190-197.	2.8	90
99	CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment. Breast Cancer Research and Treatment, 2013, 139, 649-655.	2.5	21
100	A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. International Journal of Cancer, 2013, 133, 929-936.	5.1	192
101	Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?. Nature Reviews Clinical Oncology, 2012, 9, 529-541.	27.6	63
102	Importance of highly selective LCâ€“MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen. Breast Cancer Research and Treatment, 2012, 133, 793-798.	2.5	38
103	Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers. Cellular and Molecular Life Sciences, 2012, 69, 223-245.	5.4	59
104	Impact of mammographic screening on the detection of good and poor prognosis breast cancers. Breast Cancer Research and Treatment, 2011, 130, 725-734.	2.5	76
105	Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice. Annals of Oncology, 2011, 22, 2021-2030.	1.2	19
106	An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Annals of Oncology, 2011, 22, 1561-1570.	1.2	150
107	The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Research and Treatment, 2010, 120, 655-661.	2.5	242
108	The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment. Annals of Oncology, 2010, 21, 40-47.	1.2	56

#	Article	IF	Citations
109	Estrogen Receptor-Î± Phosphorylation at Serine-118 and Tamoxifen Response in Breast Cancer. Journal of the National Cancer Institute, 2009, 101, 1725-1729.	6.3	55
110	Gene expression profiling in breast cancer â€“ design of a pooled database to address open questions. European Surgery - Acta Chirurgica Austriaca, 2009, 41, 221-227.	0.7	3
111	Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Research and Treatment, 2009, 117, 483-495.	2.5	154
112	Phosphorylation of the oestrogen receptor Î± at serine 305 and prediction of tamoxifen resistance in breast cancer. Journal of Pathology, 2009, 217, 372-379.	4.5	54
113	Clinical relevance of the triple-negative breast cancer concept: Genetic basis and clinical utility of the concept. European Journal of Cancer, 2009, 45, 11-26.	2.8	60
114	Selective benefit of high-dose, platinum-containing, alkylating chemotherapy with stem cell rescue for patients with breast cancers with an expansive growth pattern on histology. Journal of Clinical Oncology, 2009, 27, 587-587.	1.6	2
115	Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncology, The, 2007, 8, 1079-1087.	10.7	268
116	Treating the genetic make-up of breast cancer: a new fashion?. Expert Review of Anticancer Therapy, 2007, 7, 1065-1067.	2.4	2